Dasatinib and Quercetin to Treat Fibrotic Non-alcoholic Fatty Liver Disease

Prior treatment

• Bariatric surgery
• ingestion of drugs known to produce hepatic steatosis including corticosteroids, high-dose oestrogens, methotrexate, tetracycline or amiodarone in the previous 6 months
• Haemostasis disorders or current treatment with anticoagulants
• Use of prescribed drugs dependent on CYP3A4 with narrow therapeutic window and strong inducers or inhibitors of CYP3A4
• Use of H2-antagonists and/or Proton Pump Inhibitors

Other illness

• Evidence of another form of liver disease
• History of sustained excess alcohol ingestion: daily consumption \>30g/day (3 drinks per day) for males and \>20 g/day (2 drinks per day) for females
• Significant systemic or major illnesses other than liver disease, including congestive heart failure (class C and D of the AHA), unstable coronary artery disease, cerebrovascular disease, pulmonary disease, renal failure, organ transplantation, serious psychiatric disease, active malignancy, compromised immunity
• Type 1 diabetes
• History of/or current cardiac dysrhythmias and/or a history of cardiovascular disease event, including myocardial infarction, except patients with only well controlled hypertension

Lab values

• Unstable metabolic condition: weight change \> 5 kg in the last three months, diabetes with poor glycaemic control (HbA1c \> 8.5%), introduction of an antidiabetic or of an anti-obesity drug/malabsorptive or restrictive bariatric (weight loss) surgery in the past 6 months prior to screening
• QTc \>450 msec on ECG

Other

• Pregnancy/lactation or inability to adhere to adequate contraception in woman of childbearing potential
• Body mass index (BMI) \>45 kg/m2
• Contra-indication to liver biopsy

• Adult individuals, age \> 18 years
• NAFLD with fibrosis score \>2 according to the Steatosis Activity and Fibrosis score, but no cirrhosis histological diagnosis according to the SAF fibrosis score on a liver biopsy performed \< 6 months before screening in the study and confirmed by central reading during the screening period.
• Individuals agrees to have a liver biopsy performed after the treatment
• Compensated liver disease with the following hematologic and biochemical criteria on entry into protocol:
  • ALAT \<10x ULN
  • Hemoglobin \> 11g/dL for females and 12 g/dL for males
  • White blood cell (WBC) \> 2.5 K/ μL
  • Neutrophil count \> 1.5 K μL
  • Platelets \> 100 K/μL
  • Total bilirubin \<35 μmol/L
  • Albumin \>30 g/L
  • TP \>80% or INR \<1.4
  • Serum creatinine \<1.3 mg/dL (men) or \<1.1 mg/dL (women) or estimated glomerular filtration rate (eGFR) \> 60mL/min/1.73m2
• Have a stable weight since the liver biopsy was performed defined by no more than a 5% loss of initial body weight
• Subjects should be able to give informed consent